IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

NCT03457649 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
62
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

argenx